Treatment with autologous dendritic cells in a native state or directed ex vivo toward a tolerogenic immunosuppressive state is safe and well-tolerated. Dendritic cells upregulated the frequency of a potentially beneficial B220+ CD11c2 B-cell population, at least in type 1 diabetes autoimmunity. Here, PTPRC is linked to type 1 diabetes mellitus.